microRNA‑25 promotes osteosarcoma cell proliferation by targeting the cell‑cycle inhibitor p27

Wang,Xiu‑Hui; Cai,Pan; Wang,Ming‑Hui; Wang,Zhe

doi:10.3892/mmr.2014.2260

microRNA‑25 promotes osteosarcoma cell proliferation by targeting the cell‑cycle inhibitor p27

Authors:
- Xiu‑Hui Wang
- Pan Cai
- Ming‑Hui Wang
- Zhe Wang
View Affiliations

Affiliations: Department of Orthopaedics, Pudong New Area Zhoupu Hospital, Shanghai 201318, P.R. China, Clinical Medical College, China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: May 21, 2014 https://doi.org/10.3892/mmr.2014.2260
Pages: 855-859

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An increasing body of evidence indicates that microRNAs (miRNAs), a class of small non‑coding RNAs, are often aberrantly expressed in human osteosarcoma. This study aimed to investigate the effects of miR‑25 and to identify its potential target genes in osteosarcoma (OS) cells. First, the expression of miR‑25 was detected by reverse transcription‑quantitative polymerase chain reaction (RT-qPCR), which revealed a significant upregulation of miR‑25 in osteosarcoma tissues compared to the adjacent healthy tissues. To investigate the role of miR‑25 in osteosarcoma cell proliferation, the miR‑25 precursor was next transfected into Saos‑2 and U2OS cells. Overexpression of miR‑25 promoted cell proliferation in vitro and tumor growth in a xenograft mouse model. In addition, our results revealed that the protein expression of p27, a cell‑cycle inhibitor, is negatively regulated by miR‑25. Restoring the p27 level in miR‑25‑overexpressing cells reversed the enhancing effect of miR‑25 on cell proliferation. Therefore, miR‑25 may act as an onco‑miRNA in osteosarcoma, which provides new perspectives in cancer treatment strategies based on molecular targeting.

View Figures

View References

1	Sun K and Lai EC: Adult-specific functions of animal microRNAs. Nat Rev Genet. 14:535–548. 2013. View Article : Google Scholar : PubMed/NCBI
2	van Kouwenhove M, Kedde M and Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 11:644–656. 2011.PubMed/NCBI
3	Ameres SL and Zamore PD: Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488. 2013. View Article : Google Scholar : PubMed/NCBI
4	Kasinski AL and Slack FJ: Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
5	Liang W, Gao B, Fu P, Xu S, Qian Y and Fu Q: The miRNAs in the pathgenesis of osteosarcoma. Front Biosci (Landmark Ed). 18:788–794. 2013. View Article : Google Scholar : PubMed/NCBI
6	Cai CK, Zhao GY, Tian LY, et al: miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep. 28:1764–1770. 2012.PubMed/NCBI
7	Jin Y, Peng D, Shen Y, et al: MicroRNA-376c inhibits cell proliferation and invasion in osteosarcoma by targeting to transforming growth factor-alpha. DNA Cell Biol. 32:302–309. 2013. View Article : Google Scholar : PubMed/NCBI
8	Zhao G, Cai C, Yang T, et al: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 8:e539062013. View Article : Google Scholar : PubMed/NCBI
9	Li LM, Hu ZB, Zhou ZX, et al: Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 70:9798–9807. 2010. View Article : Google Scholar : PubMed/NCBI
10	Hu Z, Dong J, Wang LE, et al: Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis. 33:828–834. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhao H, Wang Y, Yang L, Jiang R and Li W: MiR-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 385:207–213. 2014. View Article : Google Scholar : PubMed/NCBI
12	Li Q, Zou C, Zou C, et al: MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett. 335:168–174. 2013. View Article : Google Scholar : PubMed/NCBI
13	Chu IM, Hengst L and Slingerland JM: The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 8:253–267. 2008. View Article : Google Scholar : PubMed/NCBI
14	Frescas D and Pagano M: Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 8:438–449. 2008. View Article : Google Scholar : PubMed/NCBI
15	Mitrea DM, Yoon MK, Ou L and Kriwacki RW: Disorder-function relationships for the cell cycle regulatory proteins p21 and p27. Biol Chem. 393:259–274. 2012. View Article : Google Scholar : PubMed/NCBI
16	Kitagawa K and Kitagawa M: The SCF ubiquitin ligases involved in hematopoietic lineage. Curr Drug Targets. 13:1641–1648. 2012. View Article : Google Scholar : PubMed/NCBI
17	Maran A, Shogren KL, Benedikt M, Sarkar G, Turner RT and Yaszemski MJ: 2-methoxyestradiol-induced cell death in osteosarcoma cells is preceded by cell cycle arrest. J Cell Biochem. 104:1937–1945. 2008. View Article : Google Scholar : PubMed/NCBI
18	Giglio S, Cirombella R, Amodeo R, Portaro L, Lavra L and Vecchione A: MicroRNA miR-24 promotes cell proliferation by targeting the CDKs inhibitors p27Kip1 and p16INK4a. J Cell Physiol. 228:2015–2023. 2013. View Article : Google Scholar : PubMed/NCBI
19	Fu Y, Liu X, Zhou N, et al: MicroRNA-200b stimulates tumour growth in TGFBR2-null colorectal cancers by negatively regulating p27/kip1. J Cell Physiol. 229:772–782. 2014. View Article : Google Scholar : PubMed/NCBI
20	Kedde M, van Kouwenhove M, Zwart W, Oude Vrielink JA, Elkon R and Agami R: A Pumilio-induced RNA structure switch in p27-3′ UTR controls miR-221 and miR-222 accessibility. Nat Cell Biol. 12:1014–1020. 2010.PubMed/NCBI